Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Language
Publication year range
1.
Exp Parasitol ; 200: 1-6, 2019 May.
Article in English | MEDLINE | ID: mdl-30904692

ABSTRACT

Nucleoside triphosphate diphosphohydrolase (NTPDase) 1 from intracellular amastigotes of Leishmania infantum-infected macrophage was identified by immunocytochemistry and confocal laser scanning microscopy using antibodies that specifically recognize its B-domain. This enzyme was previously characterized in Leishmania promastigote form, and here it is shown to be susceptible to pentamidine isethionate (PEN). In initial assays, this antileishmanial compound (100 µM) reduced 60% phosphohydrolytic activity of promastigotes preparation. An active NTPDase 1 was then isolated by non-denaturing gel electrophoresis, and PEN (10 µM) inhibited 74% and 35% of the ATPase and ADPase activities, respectively, of this pure protein. In addition, PEN 0.1-1 µM inhibited 56% potato apyrase activity, a plant protein that shares high identity with Leishmania NTPDase 1. In contrast, amphotericin B, fluconazole, ketoconazole or allopurinol did not significantly affect phosphohydrolytic activity of either promastigotes preparation or potato apyrase. This work suggests amastigote NTPDase 1 as a new molecular target, and inhibition of its catalytic activity by pentamidine can be part of the mode of action of this drug contributing with the knowledge of its antileishmanial effect.


Subject(s)
Antiprotozoal Agents/pharmacology , Apyrase/antagonists & inhibitors , Leishmania infantum/drug effects , Leishmania infantum/enzymology , Pentamidine/pharmacology , Animals , Antigens, CD , Immunohistochemistry , Macrophages/parasitology , Male , Mice , Mice, Inbred BALB C , Microscopy, Confocal
2.
Mem. Inst. Oswaldo Cruz ; 104(8): 1100-1110, Dec. 2009. ilus, tab
Article in English | LILACS | ID: lil-538169

ABSTRACT

The current drug options for the treatment of chronic Chagas disease have not been sufficient and high hopes have been placed on the use of genomic data from the human parasite Trypanosoma cruzi to identify new drug targets and develop appropriate treatments for both acute and chronic Chagas disease. However, the lack of a complete assembly of the genomic sequence and the presence of many predicted proteins with unknown or unsure functions has hampered our complete view of the parasite's metabolic pathways. Moreover, pinpointing new drug targets has proven to be more complex than anticipated and has revealed large holes in our understanding of metabolic pathways and their integrated regulation, not only for this parasite, but for many other similar pathogens. Using an in silicocomparative study on pathway annotation and searching for analogous and specific enzymes, we have been able to predict a considerable number of additional enzymatic functions in T. cruzi. Here we focus on the energetic pathways, such as glycolysis, the pentose phosphate shunt, the Krebs cycle and lipid metabolism. We point out many enzymes that are analogous to those of the human host, which could be potential new therapeutic targets.


Subject(s)
Humans , Drug Discovery , Genome, Protozoan/genetics , Metabolic Networks and Pathways/genetics , Trypanocidal Agents , Trypanosoma cruzi/metabolism , Genome, Protozoan/drug effects , Trypanosoma cruzi/chemistry , Trypanosoma cruzi/genetics
3.
Mem Inst Oswaldo Cruz ; 104(8): 1100-10, 2009 Dec.
Article in English | MEDLINE | ID: mdl-20140370

ABSTRACT

The current drug options for the treatment of chronic Chagas disease have not been sufficient and high hopes have been placed on the use of genomic data from the human parasite Trypanosoma cruzi to identify new drug targets and develop appropriate treatments for both acute and chronic Chagas disease. However, the lack of a complete assembly of the genomic sequence and the presence of many predicted proteins with unknown or unsure functions has hampered our complete view of the parasite's metabolic pathways. Moreover, pinpointing new drug targets has proven to be more complex than anticipated and has revealed large holes in our understanding of metabolic pathways and their integrated regulation, not only for this parasite, but for many other similar pathogens. Using an in silicocomparative study on pathway annotation and searching for analogous and specific enzymes, we have been able to predict a considerable number of additional enzymatic functions in T. cruzi. Here we focus on the energetic pathways, such as glycolysis, the pentose phosphate shunt, the Krebs cycle and lipid metabolism. We point out many enzymes that are analogous to those of the human host, which could be potential new therapeutic targets.


Subject(s)
Drug Discovery , Genome, Protozoan/genetics , Metabolic Networks and Pathways/genetics , Trypanocidal Agents , Trypanosoma cruzi/metabolism , Genome, Protozoan/drug effects , Humans , Trypanosoma cruzi/chemistry , Trypanosoma cruzi/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...